Homocysteina
      
   
 
 
Homocysteina u dzieci ze schyłkową niewydolnością nerek przed i po rozpoczęciu dializoterapii
 
Katarzyna Zachwieja, H. Gozdecka, Jacek A.Pietrzyk, Dorota Drożdż, Paweł Dyras
Zakład i Oddział Dializ Katedry Pediatrii
 
PIŚMIENNICTWO

  1. 1. Alakeel J., Gader A., Hurieb S. et al.: Coagulation inhibitors and fibrynolytic parameters in patients on peritoneal dialysis and hemodialysis. Int. Urol. Nephrol., 1996, 28, 255-61.

  2. Arnadottir M., Hultberg B., Nilson-Ehle P. et al.: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand. J. Clin. Lab. Invest., 1996, 56, 41-6.

  3. Bachmann J., Tepel M., Raidt H. et al.: Hyperhomocysteinemia and risk factor for vascular disease in hemodialysis patients. J. Am. Soc. Nephrol., 1995, 6, 121-5.

  4. Bertoli S.U.di., Begiojoso G.B., Trezzi M. et al.: Reduced blood levels of coagulation inhibitors in chronic hemodialysis compared with CAPD. Adv. Perit. Dial., 1995, 11, 127-30.

  5. Bienvenu T., Ankri A., Chadefaux B. et al.: Elevated total plasma homocysteine, a risk for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb. Res., 1993, 15, 123-9.

  6. Bienvenu T., Chadefaux B., Ankri A. et al: Antihtrombin III activity is not related to plasma homocysteine concentrations. Haemostasis, 1991, 21, 65-7.

  7. Bjorke Monsen A.J., Ueland P.M., Schneede J. et al.: Elevated plasma homocysteine and C677T mutation of the methylenetetrahydrofolate reductase gene in patients with spina bifida. QJM, 1997, 90, 593-596.

  8. Bostom A., Brosman J., Hall B. et al.: Net uptake of plasma homocysteine by rat kidney in vivo. Atherosclerosis, 1995, 116, 59-62.

  9. Bostom A., Lathrop L.: Hyperhomocystienemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerosis outcomes. Kidney Int., 1997, 52, 10-20.

  10. Bostom A., Shemin D., Lapane K. et al.: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis, 1996, 123 ,193-202.

  11. Bostom A., Shemin D., Lapane K. et al.: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int.,1996, 49, 147-152.

  12. Bostom A., Shemin D., Lapane K. et al.: Hyperhomocysteinemia and traditional cardivascular disease risk factors in end-stage renal disease patients on dialysis: a case control study. Atherosclerosis, 1995, 114, 93-103.

  13. Boushey C., Shirley A., Beresford A. et al.: A quantitive assessment of plasma homocysteine as a risk factor of vascular disease. JAMA, 1995, 274, 1049-1057.

  14. Chauveau P., Chadefaux B., Coude M. et al.: Hyperhomocysteinemia, a risk factor for athersosclerosis in chronic uremic patients. Kidney Int., 1993, 43, 72-77.

  15. Chauveau P., Chadefaux B., Coude M. et al.: Long term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner. Electrolyte Metab., 1996, 22, 106-9.

  16. Clarke R., Daly L., Robinson K. et al.: Hyperhomocysteinemia: an independent risk factor for vascular disaese. N. Engl. J. Med., 1991, 324, 1149-55.

  17. Clyne N., Lins L., Egberg N.: Long-term effects of erythropoetin treatment on the coagulation system during standardized hemodialysis. Clin. Nephrol., 1995, 43, 260-7.

  18. Crocker J., McDonald A., Acott P.D.: Homocysteine levels in pediatric dialysis patients treated with folic acid, vitamin B6, and vitamin B12. 31st Annual Meeting&Scientific Exposition, American Society of Nephrology,1998, A1184.

  19. De Laet C., Wautrecht J.C., Brasseur D. et al.: Plasma homocysteine concentration in Belgian school-age population. Am. J. Clin. Nutr., 1999, 69, 968-972.

  20. Demicheli M., Contino L., Iberti M. et al.: Protein C and protein S levels in uremic patients before and after dialysis. Thromb. Res., 1992, 68, 451-457.

  21. Dennis V.W., Robinson K.: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int., 1996, 50, S11-S17.

  22. Dmoszyńska A., Soroko-Wojtaszko M.: Znaczenie diagnostyczne oznaczania kompleksów TAT, PAP, fragmentów protrombiny F1+F2. W: Dmoszyńska A.: Skazy krwotoczne i zakrzepowe. Wyd.Folium, Lublin, 1997, 55-59.

  23. Domagała B., Krzanowski M., Libura M. et al.: Hyperhomocysteinemia in early onset atherosclerosis vascular disease. Acta Angiol., 1996, 2, 265-269.

  24. Ducloux D., Fournier V., Rebibou R. et al..: Hyperhomocysteinemia in renal transplant recipients with and without cyclosporine. Clin Nephrol., 1998, 49, 232-235.

  25. Dudman N., Guo Xue-Wei., Gordon R. et al.: Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J. Nutr., 1996, 126, 1295S-3000S.

  26. Fermo I., Vigano D'Angelo S., Paroni R. et al.: Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann. Intern. Med., 1995, 123, 747-53.

  27. Fodinger F., Mannhalter C., Wolfl G.et al.: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int., 1997, 52, 517-523.

  28. Fryer R.H., Wilson B.D., Gubler D.B. et al.: Homocysteine, a risk for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler. Thromb., 1993, 13, 1327-33.

  29. Greenlund K.J., Srinivasan S.R., Xu J.H.et al.: Plasma homocysteine distribution and its association with parental history of coronary artery disease in black and white children: the bogalusa heart study. Circulation,1999, 99, 2144-2149.

  30. Guba S., Fink L., Fonseca V.: Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease. Am. J. Clin. Pathol., 1996, 106, 709-22.

  31. Guttormsen A., Ueland P., Nesthus I. et al.: Determinants and vitamin responsivness of intermediate hyperhomocysteinemia (>or = 40 mmol/l). The Hordaland Homocysteine Study. J.Clin. Invest., 1996, 1, 2174-83.

  32. Guttormsen A., Ueland P., Svarstad E. et al.: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int., 1997, 52, 495-502.

  33. Harpel P., Zhang X., Borth W.: Homocysteine and hemostasis: pathogenic mechanizm predisposing to thrombosis. J. Nutr., 1996, 126, 1285S-9S.

  34. Hayashi T., Honda G., Suzuki K.: An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood, 1992, 79, 2930-6.

  35. Hultberg B., Andersson A., Sterner G.: Plasma homocysteine in renal failure. Clin. Nephrol., 1993, 40, 30-5.

  36. Ishii Y., Yano S., Kanai H. et al..: Evaluation of blood coagulation-fibrynolysis system in patients receiving chronic hemodialysis. Nephron, 1996, 73, 407-412.

  37. Janssen M., Van Guldener C., De Jong G. et al.: Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab., 1996, 22, 110-4.

  38. Jones C., Andrew M., Eddy A. et al.: Coagulation abnormalities in chronic peritoneal dialysis. Pediatr. Nephrol., 1990, 4, 152-5.

  39. Lentz S., Sadler J.: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J. Clin. Invest., 1991, 88, 1906-14.

  40. Lilien M., Duran M., Van Hoeck K. et al.: Hyperhomocysteinemia in children with chronic renal failure. Nephrol.Dial.Trans., 1999, 14, 366-368.

  41. Litwin M., Grenda R., Cichocka E.: Hiperhomocysteinemia u dzieci z przewlekłą, przeddializacyjną niewydolnością nerek - efekt leczenia kwasem foliowym:doniesienie wstępne. Plakat. II Sympozjum Nefrologii Dziecięcej, Nałęczów, 1998.

  42. Litwin M., Grenda R., Łukasiewicz H. et al.: Aktywność inhibitorów krzepnięcia u dzieci ze schyłkową niewydolnością nerek - znaczenie hiperhomocysteinemii i kwasu foliowego. III Sympozjum PTND, Przeg.Ped., 1999, 29, 169.

  43. Litwin M., Łukasiewicz H., Grenda R. et al.: Ocena wybranych parametrów układu krzepnięcia i testów nadkrzepliwości u dzieci ze schyłkową niewydolnością nerek i leczonych ciągłą ambulatoryjną dializą otrzewnową. Ped. Pol., 1997, 72, 37-43.

  44. Łopaciuk S.:Trombofilia. W: Łopaciuk S.: Zakrzepy i zatory. PZWL,Warszawa, 1996, 63-64. 4

  45. Mansoor M., Svardal A., Ueland P.: Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma. Anal. Biochem., 1992, 200, 218-229.

  46. Massy Z. A.: Hiperhomocysteinaemia in renal failure - what are the implications ? Nephrol Dial Trans., 1996, 11 Editorial comm., 2392-2393.

  47. Maurin N., Fitzner S., Fritz H. et al.: Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.Clin. Nephrol., 1995, 43, 196-200.

  48. McCully K.: Chemical pathology of homocysteine. I. Atherogenesis. Ann. Clin. Lab. Sci., 1993, 23, 477-93.

  49. Mezzano D., Tagle R., Panes O. et al.: Hemostatic disorder of uremia: the platelet defect, main determination of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb. Haemost., 1996, 76, 321-21.

  50. Myśliwiec M.: Zakrzepy w chorobach nerek. W: Łopaciuk S.: Zakrzepy i zatory. PZWL, Warszawa, 1996, 199-208.

  51. Nurko S., Moustapha A., Robinson K. et al.: Prevalence and determinants of hyper-homocysteinemia in patients on peritoneal (PD) or hemodialysis (HD). 31st Annual Meeting&Scientific Exposition, American Society of Nephrology,1998, M321.

  52. Osganian S.K., Stampfer M.J., Spiegelman D. et al.: Distribution of anf factors associated with serum homocysteine levels in children: child nad adolescent trial for cardiovascular health. JAMA, 1999, 281, 1189-1196.

  53. Perna A., Ingrosso D., Santo N. et al.: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int., 1995, 47, 247-253.

  54. Pietrzyk J.A.: Ocena skuteczności dializy u dzieci na podstawie parametrów modelowania kinetycznego mocznika. DWN, Kraków, 1994.

  55. Refsum H., Wesenberg F., Ueland P.M.: Plsama homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res., 1991, 51, 828-835.

  56. Robinson K., Gupta A., Dennis V. et al.: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation, 1996, 94, 2743-2748.

  57. Schroder C.H., Giesen A., Bloom H. et al.: Treatment of hyperhomocysteinemia in children on dialysis by folic acid. Pediatr.Nephrol., 1997, 11, C71.

  58. Shemin D., Kanaan E., Lapane K. et al.: Total homocysteine levels predict hemodialysis access thrombosis: a prospective study. 31st Annual Meeting&Scientific Exposition, American Society of Nephrology,1998, MI256.

  59. Skotnicki A.B., Sacha T.: Zaburzenia krzepnięcia krwi. Wyd.Med.Prakt., Kraków, 1997.

  60. Tamura T., Bergman S., Morgan S.: Homocysteine, B vitamins and vascular-access thrombosis in patients treated with hemodialysis. Am. J. Kidney Dis., 1998, 32, 475-481.

  61. Tkaczyk M., Owczarek D., Jander A.: Wskaźniki układu krzepnięcia i fibrynolizy u przewlekle dializowanych dzieci i młodych dorosłych. III Sympozjum PTND, Przeg.Ped., 1999, 29, 169.

  62. Tomura S., Nakamura Y., Doi M. et al.: Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipids as cardivascular risk factor in chronic hemodialysis and continous ambulatory peritoneal dialysis patients. Am. J. Kidney Dis., 1996, 27, 848-854.

  63. Tonstad S., Refsum H., Ose L. et al.: The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. J. Pediatr., 1998, 132, 365-368.

  64. Tonstad S., Refsum H., Siversten M. et al.: Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives. Pediatr. Res., 1996, 40, 47-52.

  65. Tonstad S., Refsum H., Ueland P.: Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia. Circulation, 1997, 96, 1803-1808.

  66. Van Beynum I.M., Smeitink J.A., Heijer M. et al.: Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation, 1999, 99, 2070-2072.

  67. Van der Put N.M., Thomas C.M., Eskes T.K. et al.: Altered folate and vitamin B12 metabolism in families with spina bifida offspring. QJM, 1997, 90, 505-510.

  68. Van-der-Berg M., Boers G., Franken D. et al: Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur. J. Clin. Invest., 1995, 25, 176-81.
 
   
 
 
 
 
 
 
 
 
DIALIZOTERAPIA DZIECIĘCA
      
           
         
.